Chaitanya Mamillapalli
Endocrinology, Diabetes & Metabolism · Springfield, ILNPI 1710137930
Payments from drug & device makers
Across 90 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Novo Nordisk$259
- Amgen$226
- Corcept Therapeutics$150
- Perspectum Diagnostics Ltd$149
- AbbVie$101
- plus $776 from 24 others
What the payments were for
- Food & beverage$1,67349%
- Education$1,70951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $1,719 |
| Novo Nordisk | 11 | $259 |
| Amgen | 15 | $226 |
| Corcept Therapeutics | 9 | $150 |
| Perspectum Diagnostics Ltd | 2 | $149 |
| AbbVie | 6 | $101 |
| Madrigal Pharmaceuticals | 3 | $66 |
| Boehringer Ingelheim | 3 | $64 |
| Novartis | 2 | $57 |
| Alnylam Pharmaceuticals Inc. | 3 | $56 |
| Ascendis Pharma Endocrinology Inc | 2 | $48 |
| AstraZeneca(2 entities) | 3 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Calliditas Therapeutics US Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Radius Health, Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $31 |
| Medtronic | 1 | $30 |
| Organon | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Sandoz | 1 | $24 |
| Merck | 1 | $24 |
| Recor Medical Inc | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Lite system$1,600
How this compares
$3,381 in reported general payments places this provider in the 70th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 417 | $613,585 |
| JardianceEmpagliflozin | 146 | $125,316 |
| TymlosAbaloparatide | 24 | $90,005 |
| MounjaroTirzepatide | 69 | $74,098 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 58 | $62,667 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $61,195 |
| ForteoTeriparatide | 13 | $55,074 |
| Novolog FlexpenInsulin Aspart | 156 | $48,762 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 101 | $46,684 |
| FarxigaDapagliflozin Propanediol | 38 | $40,935 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $40,709 |
| TrulicityDulaglutide | 25 | $36,414 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $32,915 |
| Humalog Kwikpen U-100Insulin Lispro | 95 | $29,887 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $28,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $259 | $653,567472 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $33 | $176,071148 claims |
| Boehringer IngelheimJardiance | $64 | $125,316146 claims |
| Radius Health, Inc.Tymlos | $32 | $90,00524 claims |
| AstraZenecaFarxiga | $46 | $40,93538 claims |
| MerckJanuvia | $24 | $27,86617 claims |
| AbbVieSynthroid | $101 | $2,37131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Springfield
- Marina RussoSpringfield$220K
- Gabriel UwaifoSpringfield$195K
- Kevin HazardSpringfield$44K
- Liana BillingsSkokie$3.4M
- Leon FogelfeldChicago$1.5M
- Grazia AleppoChicago$1.4M
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Hiralal MaheshwariMcHenry$642K
- Wenyu HuangChicago$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.